U.S. markets closed
  • S&P Futures

    4,379.25
    -32.50 (-0.74%)
     
  • Dow Futures

    34,875.00
    -99.00 (-0.28%)
     
  • Nasdaq Futures

    14,844.00
    -193.75 (-1.29%)
     
  • Russell 2000 Futures

    2,225.00
    -12.50 (-0.56%)
     
  • Crude Oil

    73.19
    -0.43 (-0.58%)
     
  • Gold

    1,833.00
    -2.80 (-0.15%)
     
  • Silver

    25.66
    -0.12 (-0.47%)
     
  • EUR/USD

    1.1882
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.2690
    +0.0080 (+0.63%)
     
  • Vix

    17.70
    -0.61 (-3.33%)
     
  • GBP/USD

    1.3944
    -0.0013 (-0.10%)
     
  • USD/JPY

    109.5100
    +0.0490 (+0.04%)
     
  • BTC-USD

    40,006.79
    +309.62 (+0.78%)
     
  • CMC Crypto 200

    952.00
    +21.64 (+2.33%)
     
  • FTSE 100

    7,078.42
    +61.79 (+0.88%)
     
  • Nikkei 225

    27,361.18
    -421.24 (-1.52%)
     

Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

·1 min read

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET.

A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com